Home LiteratureArticle Details
PMID: 32055852 Published · ppublish English

Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference.

Neuro-oncology ·Vol. 22 ·No. 6 ·2020-00-09

Packer RJ, Iavarone A, Jones DTW, Blakeley JO, Bouffet E, Fisher MJ, Hwang E, Hawkins C, Kilburn L, MacDonald T, Pfister SM, Rood B, Rodriguez FJ, Tabori U, Ramaswamy V, Zhu Y, Fangusaro J, Johnston SA, Gutmann DH

Abstract

Gliomas are the most common primary central nervous system tumors occurring in children and adults with neurofibromatosis type 1 (NF1). Over the past decade, discoveries of the molecular basis of low-grade gliomas (LGGs) have led to new approaches for diagnosis and treatments. However, these new understandings have not been fully applied to the management of NF1-associated gliomas. A consensus panel consisting of experts in NF1 and gliomas was convened to review the current molecular knowledge of NF1-associated low-grade "transformed" and high-grade gliomas; insights gained from mouse models of NF1-LGGs; challenges in diagnosing and treating older patients with NF1-associated gliomas; and advances in molecularly targeted treatment and potential immunologic treatment of these tumors. Next steps are recommended to advance the management and outcomes for NF1-associated gliomas.

Keywords
gliomas immunotherapy molecular-targeted therapy neurofibromatosis type 1 pilocytic astrocytomas
MeSH 主题词
Adult Animals Brain Neoplasms/diagnosis,therapy Child Disease Models, Animal Glioma/diagnosis,therapy Humans Neurofibromatosis 1/diagnosis,therapy
Article Info
Journal
Neuro-oncology
Abbr.
Neuro Oncol
ISSN
1523-5866
Published
2020-00-09
Language
English
Country/Region
England
NLM ID
100887420
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com